97 related articles for article (PubMed ID: 15975377)
1. Invited commentary.
Hiramatsu Y
Ann Thorac Surg; 2005 Jul; 80(1):257-8. PubMed ID: 15975377
[No Abstract] [Full Text] [Related]
2. Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model.
Kondo N; Suzuki Y; Wakayama F; Tamai Y; Ji K; Fukui K; Fukuda I
Ann Thorac Surg; 2005 Jul; 80(1):251-7. PubMed ID: 15975376
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass.
Tabata S; Yamaguchi S; Nagamine H; Tomita S; Arai S; Takemura H; Watanabe G
Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies.
Ahrens I; Peter K
Thromb Haemost; 2008 May; 99(5):803-4. PubMed ID: 18449408
[No Abstract] [Full Text] [Related]
5. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
7. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological approaches to studying platelet function: an overview.
Hourani SM
Methods Mol Biol; 2004; 273():73-86. PubMed ID: 15308794
[No Abstract] [Full Text] [Related]
9. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?
Aukrust P; Damas JK; Solum NO
J Am Coll Cardiol; 2004 Jun; 43(12):2326-8. PubMed ID: 15193701
[No Abstract] [Full Text] [Related]
10. Platelet activation and progression to complications.
Kereiakes DJ; Michelson AD
Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
[TBL] [Abstract][Full Text] [Related]
11. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
Mousa SA; Ahmad S
Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
[TBL] [Abstract][Full Text] [Related]
12. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Madsen NJ; Holmes CE; Serrano FA; Sobel BE; Schneider DJ
Am J Cardiol; 2007 Aug; 100(4):722-7. PubMed ID: 17697836
[TBL] [Abstract][Full Text] [Related]
13. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
[No Abstract] [Full Text] [Related]
14. Platelet-monocyte interaction and GPIIb/IIIa blockade.
Zhao L; Bath P; Lösche W; Heptinstall S
Thromb Haemost; 2004 Oct; 92(4):888-90. PubMed ID: 15467921
[No Abstract] [Full Text] [Related]
15. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
[TBL] [Abstract][Full Text] [Related]
16. GP IIb/IIIa blockade during peripheral artery interventions.
Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
Bassler N; Loeffler C; Mangin P; Yuan Y; Schwarz M; Hagemeyer CE; Eisenhardt SU; Ahrens I; Bode C; Jackson SP; Peter K
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):e9-15. PubMed ID: 17170374
[TBL] [Abstract][Full Text] [Related]
18. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Gurbel PA
Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
[TBL] [Abstract][Full Text] [Related]
19. Platelet function testing and implications for clinical practice.
Collet JP; Montalescot G
J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
[TBL] [Abstract][Full Text] [Related]
20. Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study.
Kawahito K; Fujimura A; Kobayashi E; Misawa Y; Fuse K
Artif Organs; 1998 Apr; 22(4):348-52. PubMed ID: 9555968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
